论文部分内容阅读
目的分析mi R-31、mi R-21和mi R-155在弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中的表达水平,并探讨其与DLBCL临床病理特征的关系。方法采用实时荧光定量聚合酶链反应(real-time quantitativepolymerase chain reaction,RT-PCR)检测92例DLBCL患者和84例对照mi R-31、mi R-21和mi R-155的表达水平,间期荧光原位杂交技术分析患者MYC和p53基因的异常情况,根据Hans的分类方法分为生发中心B细胞型(germinal center Bcell type,GCB型)和非生发中心B细胞型(non-GCB型)。结果 DLBCL组mi R-31、mi R-21及mi R-155表达水平高于对照组(P<0.05),mi R-31、mi R-21及mi R-155在non-GCB型的表达高于GCB型(P<0.05)。与MYC基因没有发生重排的患者相比,mi R-31、mi R-21及mi R-155在MYC重排的患者中表达下调(P<0.05)。mi R-31、mi R-21及mi R-155在p53基因丢失组的表达较基因正常组下调(P<0.05)。BCL-2蛋白阳性组mi R-31、mi R-21及mi R-155的表达较BCL-2蛋白阴性组下调(P<0.05)。Kaplan-Meier生存分析显示,mi R-31、mi R-21及mi R-155高表达的DLBCL患者生存率低于低表达的患者(P<0.05)。应用单因素和多因素Cox模型分析,发现mi R-31、mi R-21及mi R-155表达水平、免疫分型、p53基因与预后差异有统计学意义(P<0.05)。结论 mi R-31、mi R-21和mi R-155对DLBCL的诊断分型及预后判断有一定的参考价值,有望成为DLBCL治疗的新靶点。
Objective To analyze the expression of mi R-31, mi R-21 and mi R-155 in diffuse large B cell lymphoma (DLBCL) and to investigate its relationship with clinicopathological features of DLBCL. Methods The expression of mi R-31, mi R-21 and mi R-155 in 92 patients with DLBCL and 84 controls were detected by real-time quantitative polymerase chain reaction (RT-PCR) Fluorescence in situ hybridization analysis of patients with abnormalities of MYC and p53 genes, according to Hans classification method is divided into germinal center B cell type (germinal center Bcell type, GCB type) and non-germinal center B cell type (non-GCB type). Results The expressions of mi R-31, mi R-21 and mi R-155 in DLBCL group were significantly higher than those in control group (P <0.05). The expressions of mi R-31, mi R-21 and mi R- Higher than GCB type (P <0.05). Compared with patients without MYC rearrangement, mi R-31, mi R-21 and mi R-155 were down-regulated in patients with MYC rearrangement (P <0.05). The expression of mi R-31, mi R-21 and mi R-155 in p53 gene loss group was lower than that in normal gene group (P <0.05). The expression of mi R-31, mi R-21 and mi R-155 in BCL-2 positive group was lower than that in BCL-2 negative group (P <0.05). Kaplan-Meier survival analysis showed that the survival rates of DLBCL patients with high expression of mi R-31, mi R-21 and mi R-155 were lower than those with low expression (P <0.05). Using univariate and multivariate Cox model analysis, mi R-31, mi R-21 and mi R-155 expression levels, immunophenotyping, p53 gene and prognosis were statistically significant (P <0.05). Conclusion The mi R-31, mi R-21 and mi R-155 have some reference value for the diagnosis and prognosis of DLBCL, which is expected to become a new target of DLBCL therapy.